Table of Contents
Metal-Based Drugs
Volume 2010, Article ID 430939, 7 pages
http://dx.doi.org/10.1155/2010/430939
Review Article

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy

1Department of Radiation Oncology, Institute of Clinical Medicine, Medical College and Hospital, National Cheng Kung University, Tainan 70428, Taiwan
2Department of Molecular Pathology, The University of Texas-MD Anderson Cancer Center, 7453 Fannin Boulevard, Houston, TX 77054, USA

Received 14 July 2010; Accepted 25 August 2010

Academic Editor: Zhe-Sheng Chen

Copyright © 2010 Helen H. W. Chen and Macus Tien Kuo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Hussain, Y. T. Ma, and M. H. Cullen, “Management of metastatic germ cell tumors,” Expert Review of Anticancer Therapy, vol. 8, no. 5, pp. 771–784, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. M. Markman, “Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies,” Trends in Pharmacological Sciences, vol. 29, no. 10, pp. 515–519, 2008. View at Publisher · View at Google Scholar · View at PubMed
  3. F. Muggia, “Platinum compounds 30years after the introduction of cisplatin: implications for the treatment of ovarian cancer,” Gynecologic Oncology, vol. 112, no. 1, pp. 275–281, 2009. View at Publisher · View at Google Scholar · View at PubMed
  4. D. H. Moore, C. Tian, B. J. Monk, H. J. Long, G. A. Omura, and J. D. Bloss, “Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 116, no. 1, pp. 44–49, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. D. J. Gallagher and M. I. Milowsky, “Bladder cancer,” Current Treatment Options in Oncology, vol. 10, no. 3-4, pp. 205–215, 2009. View at Publisher · View at Google Scholar · View at PubMed
  6. E. S. Yang, B. M. Murphy, and B. M. Murphy, “Evolution of clinical trials in head and neck cancer,” Critical Reviews in Oncology/Hematology, vol. 71, no. 1, pp. 29–42, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. L. Kelland, “The resurgence of platinum-based cancer chemotherapy,” Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. M. B. Lustberg and M. J. Edelman, “Optimal duration of chemotherapy in advanced non-small cell lung cancer,” Current Treatment Options in Oncology, vol. 8, no. 1, pp. 38–46, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003. View at Publisher · View at Google Scholar · View at PubMed
  10. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. M. T. Kuo, “Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 11, no. 1, pp. 99–133, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219–234, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. P. Borst and R. Oude Elferink, “Mammalian ABC transporters in health and disease,” Annual Review of Biochemistry, vol. 71, pp. 537–592, 2002. View at Publisher · View at Google Scholar · View at PubMed
  14. T. Ishikawa and F. Ali-Osman, “Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance,” Journal of Biological Chemistry, vol. 268, no. 27, pp. 20116–20125, 1993. View at Google Scholar
  15. T. Ishikawa, C. D. Wright, and H. Ishizuka, “GS-X pump is functionally overexpressed in cis- diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down- regulated by cell differentiation,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 29085–29093, 1994. View at Google Scholar
  16. Y. Cui, J. König, U. Buchholz, H. Spring, I. Leier, and D. Keppler, “Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells,” Molecular Pharmacology, vol. 55, no. 5, pp. 929–937, 1999. View at Google Scholar
  17. C. C. Paulusma, M. A. van Geer, R. Evers, M. Heijn, R. Ottenhoff, P. Borst, and R. P. J. Oude Elferink, “Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione,” Biochemical Journal, vol. 338, no. 2, pp. 393–401, 1999. View at Publisher · View at Google Scholar
  18. D. W. Loe, K. C. Almquist, R. G. Deeley, and S. P. C. Cole, “Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport,” Journal of Biological Chemistry, vol. 271, no. 16, pp. 9675–9682, 1996. View at Google Scholar
  19. G. J. R. Zaman, J. Lankelma, and J. Lankelma, “Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7690–7694, 1995. View at Publisher · View at Google Scholar
  20. E. M. Leslie, K.-I. Ito, P. Upadhyaya, S. S. Hecht, R. G. Deeley, and S. P. C. Cole, “Transport of the β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1): requirement for glutathione or a non-sulfur-containing analog,” Journal of Biological Chemistry, vol. 276, no. 30, pp. 27846–27854, 2001. View at Publisher · View at Google Scholar · View at PubMed
  21. Y.-M. Qian, C. E. Grant, and C. E. Grant, “Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 35225–35231, 2002. View at Publisher · View at Google Scholar · View at PubMed
  22. L. Vernhet, M.-P. Séité, N. Allain, A. Guillouzo, and O. Fardel, “Arsenic induces expression of the multidrug resistance associated protein 2 (MRP2) gene in primary rat and human hepatocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 1, pp. 234–239, 2001. View at Google Scholar
  23. H.-M. Kauffmann, D. Keppler, J. Kartenbeck, and D. Schrenk, “Induction of cMrp/cMoat gene expression by cisplatin, 2- acetylaminofluorene, or cycloheximide in rat hepatocytes,” Hepatology, vol. 26, no. 4, pp. 980–985, 1997. View at Google Scholar
  24. M. Demeule, M. Brossard, and R. Béliveau, “Cisplatin induces renal expression of P-glycoprorein and canalicular multispecific organic anion transporter,” American Journal of Physiology—Renal Physiology, vol. 277, no. 6, part 2, pp. F832–F840, 1999. View at Google Scholar
  25. P. V. Korita, T. Wakai, Y. Shirai et al., “Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma,” Oncology Reports, vol. 23, no. 4, pp. 965–972, 2010. View at Google Scholar
  26. S. J. Berners-Price and P. W. Kuchel, “Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione inside human red blood cells, studied by 1H and 15N-{1H} dept NMR,” Journal of Inorganic Biochemistry, vol. 38, no. 4, pp. 327–345, 1990. View at Publisher · View at Google Scholar
  27. Y. Kasherman, S. Sturup, and D. Gibson, “Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts,” Journal of Medicinal Chemistry, vol. 52, no. 14, pp. 4319–4328, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. T. Ishikawa, J.-J. Bao, Y. Yamane, K. Akimaru, K. Frindrich, C. D. Wrigh, and M. Tien Kuo, “Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells,” Journal of Biological Chemistry, vol. 271, no. 25, pp. 14981–14988, 1996. View at Publisher · View at Google Scholar
  29. Y. Yamane, M. Furuichi, R. Song, T. Van Nguyen, R. T. Mulcahy, T. Ishikawa, and M. T. Kuo, “Expression of multidrug resistance protein/GS-X pump and γ- glutamylcysteine synthetase genes is regulated by oxidative stress,” Journal of Biological Chemistry, vol. 273, no. 47, pp. 31075–31085, 1998. View at Publisher · View at Google Scholar
  30. Y. Ikegami, S. Tatebe, Y. C. Lin-Lee, Q. W. Xie, T. Ishikawa, and M. T. Kuo, “Induction of MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells,” Journal of Cellular Physiology, vol. 185, no. 2, pp. 293–301, 2000. View at Google Scholar
  31. Y.-C. Lin-Lee, S. Tatebe, N. Savaraj, T. Ishikawa, and M. Tien Kuo, “Differential sensitivities of the MRP gene family and γ-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status,” Biochemical Pharmacology, vol. 61, no. 5, pp. 555–563, 2001. View at Publisher · View at Google Scholar
  32. M. T. Kuo, J.-J. Bao, S. A. Curley, M. Ikeguchi, D. A. Johnston, and T. Ishikawa, “Frequent coordinated overexpression of the MRP/GS-X pump and γ- glutamylcysteine synthetase genes in human colorectal cancers,” Cancer Research, vol. 56, no. 16, pp. 3642–3644, 1996. View at Google Scholar
  33. S. Tatebe, H. Unate, F. A. Sinicrope et al., “Expression of heavy subunit of γ-glutamylcysteine synthetase (γ-GCSh) in human colorectal carcinoma,” International Journal of Cancer, vol. 97, no. 1, pp. 21–27, 2002. View at Publisher · View at Google Scholar · View at PubMed
  34. A. K. Godwin, A. Meister, P. J. O'Dwyer, C. S. Huang, T. C. Hamilton, and M. E. Anderson, “High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 3070–3074, 1992. View at Google Scholar
  35. C. Meijer, N. H. Mulder, H. Timmer-Bosscha, W. J. Sluiter, G. J. Meersma, and E. G. E. de Vries, “Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds,” Cancer Research, vol. 52, no. 24, pp. 6885–6889, 1992. View at Google Scholar
  36. C. P. Schröder, A. K. Godwin, P. J. O'Dwyer, K. D. Tew, T. C. Hamilton, and R. F. Ozols, “Glutathione and drug resistance,” Cancer Investigation, vol. 14, no. 2, pp. 158–168, 1996. View at Google Scholar
  37. K. Mishima, A. Baba, M. Matsuo, Y. Itoh, and R. Oishi, “Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity,” Free Radical Biology and Medicine, vol. 40, no. 9, pp. 1564–1577, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. T. Sasada, H. Nakamura, S. Ueda, S. Iwata, M. Ueno, A. Takabayashi, and J. Yodoi, “Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum (II),” Antioxidants and Redox Signaling, vol. 2, no. 4, pp. 695–705, 2000. View at Google Scholar
  39. B. A. J. Jansen, J. Brouwer, and J. Reedijk, “Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs,” Journal of Inorganic Biochemistry, vol. 89, no. 3-4, pp. 197–202, 2002. View at Publisher · View at Google Scholar
  40. G. V. Z. Dedoussis and N. K. Andrikopoulos, “Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis,” European Journal of Cell Biology, vol. 80, no. 9, pp. 608–614, 2001. View at Google Scholar
  41. A. Troyano, C. Fernández, P. Sancho, E. De Blas, and P. Aller, “Effect of glutathione depletion on antitumor drug toxicity (Apoptosis and Necrosis) in U-937 human promonocytic cells: the role of intracellular oxidation,” Journal of Biological Chemistry, vol. 276, no. 50, pp. 47107–47115, 2001. View at Publisher · View at Google Scholar · View at PubMed
  42. K.-S. Yao, A. K. Godwin, S. W. Johnson, R. F. Ozols, P. J. O'Dwyer, and T. C. Hamilton, “Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines,” Cancer Research, vol. 55, no. 19, pp. 4367–4374, 1995. View at Google Scholar
  43. K. Ikeda, K. Miura, S. Himeno, N. Imura, and A. Naganuma, “Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum,” Molecular and Cellular Biochemistry, vol. 219, no. 1-2, pp. 51–56, 2001. View at Publisher · View at Google Scholar
  44. I.-S. Song, S. Tatebe, W. Dai, and M. T. Kuo, “Delayed mechanism for induction of γ-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling,” Journal of Biological Chemistry, vol. 280, no. 31, pp. 28230–28240, 2005. View at Publisher · View at Google Scholar · View at PubMed
  45. H. H. W. Chen, I.-S. Song, and I.-S. Song, “Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1,” Molecular Pharmacology, vol. 74, no. 3, pp. 697–704, 2008. View at Publisher · View at Google Scholar · View at PubMed
  46. D. D. Zhang and M. Hannink, “Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress,” Molecular and Cellular Biology, vol. 23, no. 22, pp. 8137–8151, 2003. View at Publisher · View at Google Scholar
  47. J. M. Maher, M. Z. Dieter, and M. Z. Dieter, “Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway,” Hepatology, vol. 46, no. 5, pp. 1597–1610, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Ishida, J. Lee, D. J. Thiele, and I. Herskowitz, “Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14298–14302, 2002. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Jungmann, H.-A. Reins, J. Lee, A. Romeo, R. Hassett, D. Kosman, and S. Jentsch, “MAC1, a nuclear regulatory protein related to Cu-dependent transcription factors is involved in Cu/Fe utilization and stress resistance in yeast,” EMBO Journal, vol. 12, no. 13, pp. 5051–5056, 1993. View at Google Scholar
  50. M. D. Garrick, K. G. Dolan, and K. G. Dolan, “DMT1: a mammalian transporter for multiple metals,” BioMetals, vol. 16, no. 1, pp. 41–54, 2003. View at Publisher · View at Google Scholar
  51. E. Georgatsou, L. A. Mavrogiannis, G. S. Fragiadakis, and D. Alexandraki, “The yeast Fre1p/Fre2p cupric reductases facilitate copper uptake and are regulated by the copper-modulated Mac1p activator,” Journal of Biological Chemistry, vol. 272, no. 21, pp. 13786–13792, 1997. View at Publisher · View at Google Scholar
  52. R. Hassett, D. R. Dix, D. J. Eide, and D. J. Kosman, “The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae,” Biochemical Journal, vol. 351, no. 2, pp. 477–484, 2000. View at Publisher · View at Google Scholar
  53. L. T. Jensen, M. C. Posewitz, C. Srinivasan, and D. R. Winge, “Mapping of the DNA binding domain of the copper-responsive transcription factor Mac1 from Saccharomyces cerevisiae,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 23805–23811, 1998. View at Publisher · View at Google Scholar
  54. S. Labbé, Z. Zhu, and D. J. Thiele, “Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway,” Journal of Biological Chemistry, vol. 272, no. 25, pp. 15951–15958, 1997. View at Publisher · View at Google Scholar
  55. Y. Yamaguchi-Iwai, M. Serpe, D. Haile, W. Yang, D. J. Kosman, R. D. Klausner, and A. Dancis, “Homeostatic regulation of copper uptake in yeast via direct binding of MAC1 protein to upstream regulatory sequences of FRE1 and CTR1,” Journal of Biological Chemistry, vol. 272, no. 28, pp. 17711–17718, 1997. View at Publisher · View at Google Scholar
  56. A. J. Bird, S. Swierczek, W. Qiao, D. J. Eide, and D. R. Winge, “Zinc metalloregulation of the zinc finger pair domain,” Journal of Biological Chemistry, vol. 281, no. 35, pp. 25326–25335, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. E. B. Gralla, D. J. Thiele, P. Silar, and J. S. Valentine, “ACE1, a copper-dependent transcription factor, activates expression of the yeast copper, zinc superoxide dismutase gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 19, pp. 8558–8562, 1991. View at Publisher · View at Google Scholar
  58. C. Gross, M. Kelleher, V. R. Iyer, P. O. Brown, and D. R. Winge, “Identification of the copper regulon in Saccharomyces cerevisiae by DNA microarrays,” Journal of Biological Chemistry, vol. 275, no. 41, pp. 32310–32316, 2000. View at Google Scholar
  59. A. Selvaraj, K. Balamurugan, and K. Balamurugan, “Metal-responsive transcription factor (MTF-1) handles both extremes, copper load and copper starvation, by activating different genes,” Genes and Development, vol. 19, no. 8, pp. 891–896, 2005. View at Publisher · View at Google Scholar · View at PubMed
  60. C. E. Ooi, E. Rabinovich, A. Dancis, J. S. Bonifacino, and R. D. Klausner, “Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis,” EMBO Journal, vol. 15, no. 14, pp. 3515–3523, 1996. View at Google Scholar
  61. B.-E. Kim, T. Nevitt, and D. J. Thiele, “Mechanisms for copper acquisition, distribution and regulation,” Nature Chemical Biology, vol. 4, no. 3, pp. 176–185, 2008. View at Publisher · View at Google Scholar · View at PubMed
  62. M. J. Petris, K. Smith, J. Lee, and D. J. Thiele, “Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9639–9646, 2003. View at Publisher · View at Google Scholar · View at PubMed
  63. I.-S. Song, H. H. W. Chen, I. Aiba, A. Hossain, Z. D. Liang, L. W. J. Klomp, and M. T. Kuo, “Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells,” Molecular Pharmacology, vol. 74, no. 3, pp. 705–713, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. J. H. Freedman, M. R. Ciriolo, and J. Peisach, “The role of glutathione in copper metabolism and toxicity,” Journal of Biological Chemistry, vol. 264, no. 10, pp. 5598–5605, 1989. View at Google Scholar
  65. E. D. Harris, “Cellular copper transport and metabolism,” Annual Review of Nutrition, vol. 20, pp. 291–310, 2000. View at Publisher · View at Google Scholar · View at PubMed
  66. Y. Nose, B.-E. Kim, and D. J. Thiele, “Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function,” Cell Metabolism, vol. 4, no. 3, pp. 235–244, 2006. View at Publisher · View at Google Scholar · View at PubMed
  67. S. Ishida, F. McCormick, K. Smith-McCune, and D. Hanahan, “Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator,” Cancer Cells, vol. 17, no. 6, pp. 574–583, 2010. View at Google Scholar